Ulcerative colitis affects an estimated 5 million people worldwide, making it one of the more common chronic digestive diseases. In the United States alone, roughly 286 out of every 100,000 people have the condition. While those numbers may sound small in percentage terms, they translate to a large and growing patient population, particularly in Western countries.
Global Prevalence and Where It’s Most Common
Ulcerative colitis is not evenly distributed around the world. Northern Europe and North America have the highest rates by a wide margin. Norway leads globally with a prevalence of 505 per 100,000 people, meaning roughly 1 in 200 Norwegians lives with the condition. The United States follows at 286 per 100,000, and rates in Canada and Australia are similarly elevated.
Incidence, which measures how many new cases appear each year, follows the same geographic pattern. The Faroe Islands (a small Nordic territory) report the highest annual incidence at nearly 58 new cases per 100,000 people per year. Canada sees about 23 new cases per 100,000 annually, and Australia about 17. By contrast, countries in Asia, Africa, and South America have historically reported much lower rates, though those numbers have been climbing as diets and lifestyles in those regions shift toward Western patterns.
Who Gets Ulcerative Colitis
Most people are diagnosed before age 30, though the condition can appear at any stage of life. It affects both men and women at roughly similar rates, unlike some autoimmune conditions that skew heavily toward one sex.
Race and ethnicity play a role in risk, at least within the United States. Data on inflammatory bowel disease as a whole (which includes both ulcerative colitis and Crohn’s disease) shows clear disparities. White Americans have the highest prevalence at 812 per 100,000, followed by Black Americans at 504, Hispanic Americans at 458, and Asian Americans at 403. These gaps likely reflect a combination of genetic susceptibility, environmental exposures, diet, and differences in access to diagnosis. Notably, rates among non-White populations have been rising in recent decades, challenging the older assumption that ulcerative colitis is primarily a disease of White populations.
Is It Becoming More Common?
Yes. The global case count has risen steadily over the past several decades. Part of this increase reflects better diagnostic tools and broader access to colonoscopy, especially in countries that previously had limited screening. But improved detection alone doesn’t explain the trend. Newly industrialized countries in Asia, South America, and the Middle East are seeing genuine increases in incidence, suggesting that environmental factors tied to urbanization, processed food consumption, antibiotic use, and changes in gut bacteria play a significant role.
In Western countries where rates were already high, prevalence continues to climb simply because ulcerative colitis is a lifelong condition. People diagnosed in their twenties live with it for decades, so even if the rate of new diagnoses held steady, the total number of people living with the disease would still grow over time.
How It Compares to Other Conditions
To put the numbers in context, ulcerative colitis is less common than conditions like type 2 diabetes or asthma, but it’s far from rare. In the U.S., it’s roughly as prevalent as Crohn’s disease (the other major form of inflammatory bowel disease) and more common than many conditions people consider well-known, such as celiac disease or multiple sclerosis. If you’ve been diagnosed, you’re part of a large patient community with well-established treatment pathways.
Does Ulcerative Colitis Affect Life Expectancy?
For most people, no. A long-term population study from Copenhagen found that overall life expectancy for ulcerative colitis patients was normal compared to the general population. The standardized mortality ratio was actually 0.70, suggesting no excess deaths across the full cohort over time.
There are exceptions. Patients diagnosed after age 50 who had extensive inflammation across the entire colon faced higher mortality in the first two years after diagnosis, primarily from surgical complications and coexisting health problems. Within the first year after any diagnosis, there was a small, statistically significant bump in mortality risk. After that initial period, survival curves matched the background population. Modern treatments have improved outcomes further since that study was conducted, so these already-reassuring numbers likely look even better today.
What Drives the Risk
Ulcerative colitis results from a combination of genetic predisposition and environmental triggers. Having a first-degree relative with the condition increases your risk substantially, and over 200 genetic regions have been linked to inflammatory bowel disease. But genes alone don’t determine who develops it. Identical twins share the condition only about 16% of the time, which means non-genetic factors are doing most of the work.
The leading environmental suspects include early-life antibiotic exposure, diet high in processed foods and low in fiber, urban living, and disruptions to the gut microbiome. Interestingly, former smokers have a higher risk than people who never smoked, one of the more counterintuitive findings in gastroenterology. Stress doesn’t cause ulcerative colitis, but it can trigger flares in people who already have it.